NF-kappaB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-kappaB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-kappaB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.
Host Species: human
Background
NF-kappaB signaling plays a pivotal role in regulating cell development and immune homeostasis. Activation of NF-kappaB through tumor necrosis factor receptors (TNFR) or the TNFR superfamily member CD40 occurs upon engagement with their respective ligands TNFalpha or CD40L. Activation of NF-kappaB enhances cell inflammation and prevents apoptosis, which contribute to tumor development. The A549 lung epithelial cell line is ideal in an in vitro lung disease model for high throughput screening of oncogene inhibitors upstream of the NF-kappaB signaling pathway.
Application
The NF-kappaB-luciferase / A549 cell line is suitable for monitoring the activity of NF-kappaB transcription factor through luminescence readout instead of using electrophoretic mobility shift assay (EMSA). It provides a platform to enable study of a plethora of
License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.
Product Format
Each vial contains ~3 x 106 cells in 1mL of 10% DMSO in FBS.
Storage Stability
Store in liquid nitrogen immediately upon receipt.
Reference
1. Cherfilis-Vicini J. et.al. (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120: 1285-1297.2. Chen W. et.al. (2011NF-kappaB, a mediator for lung carcinogenesis and a target for lung cancer prevention and therapy. Front. Biosci. 16: 1172-1185. 3. Callister ME et.al. (2008) PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells. Br. J. Pharm. 155: 661-672.4. Schmeck B et.al. (2007) Legionella pneumophilia-induced NF-kappaB- and MAPK-dependent cytokine release by lung epithelial cells. Eur. Respir. J. 29: 25-33